Alimera Sciences (ALIM -14%) takes a hit today after the UK's National Institute for Health and...

|About: Alimera Sciences, Inc. (ALIM)|By:, SA News Editor

Alimera Sciences (ALIM -14%) takes a hit today after the UK's National Institute for Health and Clinical Excellence issued final draft guidance indicating that Iluvien is not recommended for the treatment of chronic diabetic macular edema. The agency noted the drug was insufficiently responsive to available therapies, and that that cost-effectiveness thresholds weren't met.